105 research outputs found
Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution
Breast cancers that are triple-negative for the clinical markers ESR1, PGR, and HER2 typically belong to the Basal-like molecular subtype. Defective Rb, p53, and Brca1 pathways are each associated with triple-negative and Basal-like subtypes. Our mouse genetic studies demonstrate that the combined inactivation of Rb and p53 pathways is sufficient to suppress the physiological cell death of mammary involution. Furthermore, concomitant inactivation of all three pathways in mammary epithelium has an additive effect on tumor latency and predisposes highly penetrant, metastatic adenocarcinomas. The tumors are poorly differentiated and have histologic features that are common among human Brca1-mutated tumors, including heterogeneous morphology, metaplasia, and necrosis. Gene expression analyses demonstrate that the tumors share attributes of both Basal-like and Claudin-low signatures, two molecular subtypes encompassed by the broader, triple-negative class defined by clinical markers
Genome position and gene amplification
Genomic analyses of human cells expressing dihydrofolate reductase provide insight into the effects of genome position on the propensity for a drug-resistance gene to amplify in human cells
Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility
11 páginas, 5 figuras, 1 tabla.-- et al.[Background]: Germline polymorphisms can influence gene expression networks in normal mammalian tissues and can affect disease susceptibility. We and others have shown that analysis of this genetic architecture can identify single genes and whole pathways that influence complex traits, including inflammation and cancer susceptibility. Whether germline variants affect gene expression in tumors that have undergone somatic alterations, and the extent to which these variants influence tumor progression, is unknown.
[Results]: Using an integrated linkage and genomic analysis of a mouse model of skin cancer that produces both benign tumors and malignant carcinomas, we document major changes in germline control of gene expression during skin tumor development resulting from cell selection, somatic genetic events, and changes in the tumor microenvironment. The number of significant expression quantitative trait loci (eQTL) is progressively reduced in benign and malignant skin tumors when compared to normal skin. However, novel tumor-specific eQTL are detected for several genes associated with tumor susceptibility, including IL18 (Il18), Granzyme E (Gzme), Sprouty homolog 2 (Spry2), and Mitogen-activated protein kinase kinase 4 (Map2k4).
[Conclusions]: We conclude that the genetic architecture is substantially altered in tumors, and that eQTL analysis of tumors can identify host factors that influence the tumor microenvironment, mitogen-activated protein (MAP) kinase signaling, and cancer susceptibility.This work was supported by the National Cancer Institute. AB acknowledges
support from the Barbara Bass Bakar Chair of Cancer Genetics. MDT was
supported in part by a Sandler Foundation postdoctoral research fellowship.
JS was supported by the Swedish Research Council and the Tegger
Foundation. KKL was supported by an NIH Kirschstein-NRSA postdoctoral
research fellowship. JPL is partially supported by Carlos III (FIS)/FEDER,
MICIIN/plan-E 2009, JCyL (’Biomedicina y Educación’) and CSIC. The funders
had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.Peer reviewe
Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer
Despite the recent consensus on the eligibility of adjuvant
systemic therapy in patients with lymph node–negative breast
cancer (NNBC) based on clinicopathologic criteria, specific
biological markers are needed to predict sensitivity to the
different available therapeutic options.W e examined the feasibility
of developing a genomic predictor of chemotherapy
response and recurrence risk in 185 patients with NNBC using
assembled arrays containing 2,460 bacterial artificial chromosome
clones for scanning the genome for DNA copy number
changes.Aft er surgery, 90 patients received anthracyclinebased
chemotherapy, whereas 95 did not.T amoxifen was administered
to patients with hormone receptor–positive tumors.
The association of genomic and clinicopathologic data and
outcome was computed using Cox proportional hazard models
and multiple testing adjustment procedures.Analysis of NNBC
genomes revealed a common genomic signature.Specific DNA
copy number aberrations were associated with hormonal
receptor status, but not with other clinicopathologic variables.
In patients treated with chemotherapy, none of the genomic
changes were significantly correlated with recurrence.In
patients not receiving chemotherapy, deletion of eight bacterial
artificial chromosome clones clustered to chromosome 11q
was independently associated with relapse (disease-free survival
at 10 years F SE, 40% F 14% versus 86% F 6%; P < 0.0001).
The 54 patients with deletion of 11q (29%) did not present more
aggressive clinicopathologic features than those without 11q
loss.The adverse influence of 11q deletion on clinical outcome
was confirmed in an independent validation series of 88
patients with NNBC.Our data suggests that patients with NNBC
with the 11q deletion might benefit from anthracycline-based
chemotherapy despite other clinical, pathologic, or genetic
features.However , these initial findings should be evaluated
in randomized clinical trials
Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells
INTRODUCTION: Cyclin E, a G(1 )cyclin essential for G(1)–S phase transition, is known to have a profound effect on tumorigenesis. Elevated levels of cyclin E have been associated with breast cancer, and chromosomal instability observed in breast cancer is suggested to be associated with constitutive expression of cyclin E. It was previously demonstrated that SUM149PT human breast cancer cells show very high levels of cyclin E expression by western analysis and that they express a nonfunctional cyclin E ubiquitin ligase due to a mutation in the F-box protein hCdc4. METHODS: We examined cyclin E expression in both MCF10A and SUM149PT cells using western blot analysis and flow cytometry. Immunofluorescence was utilized for the localization of cyclin E in both normal and breast cancer cells. In addition, array comparative genomic hybridization analysis was performed to compare chromosome copy number alterations with levels of cyclin E expression among a panel of breast cancer cell lines. RESULTS: SUM149PT cells overexpress cyclin E on a cell per cell basis for the duration of the cell cycle. High cyclin E levels are maintained throughout the S phase, and SUM149PT cells exhibit an S phase delay or arrest probably due to cyclin E overexpression. In addition, comparative genomic hybridization indicated that SUM149PT cells exhibit many chromosome copy number alterations, which may reflect prior or ongoing genomic instability. However, no direct correlation was observed between cyclin E levels and genomic copy number alteration in a panel of human breast cancer cell lines. CONCLUSIONS: Cyclin E is overexpressed at high levels throughout the cell cycle in SUM149PT cells, which is in stark contrast to cyclin E degradation observed in the mid to late S phase of normal cells. SUM149PT cells are unable to regulate cyclin E and also exhibit many copy number alterations. However, there was a lack of direct correlation between cyclin E overexpression and chromosomal instability across a panel of other breast cancer cell lines examined
Breast tumor copy number aberration phenotypes and genomic instability
BACKGROUND: Genomic DNA copy number aberrations are frequent in solid tumors, although the underlying causes of chromosomal instability in tumors remain obscure. Genes likely to have genomic instability phenotypes when mutated (e.g. those involved in mitosis, replication, repair, and telomeres) are rarely mutated in chromosomally unstable sporadic tumors, even though such mutations are associated with some heritable cancer prone syndromes. METHODS: We applied array comparative genomic hybridization (CGH) to the analysis of breast tumors. The variation in the levels of genomic instability amongst tumors prompted us to investigate whether alterations in processes/genes involved in maintenance and/or manipulation of the genome were associated with particular types of genomic instability. RESULTS: We discriminated three breast tumor subtypes based on genomic DNA copy number alterations. The subtypes varied with respect to level of genomic instability. We find that shorter telomeres and altered telomere related gene expression are associated with amplification, implicating telomere attrition as a promoter of this type of aberration in breast cancer. On the other hand, the numbers of chromosomal alterations, particularly low level changes, are associated with altered expression of genes in other functional classes (mitosis, cell cycle, DNA replication and repair). Further, although loss of function instability phenotypes have been demonstrated for many of the genes in model systems, we observed enhanced expression of most genes in tumors, indicating that over expression, rather than deficiency underlies instability. CONCLUSION: Many of the genes associated with higher frequency of copy number aberrations are direct targets of E2F, supporting the hypothesis that deregulation of the Rb pathway is a major contributor to chromosomal instability in breast tumors. These observations are consistent with failure to find mutations in sporadic tumors in genes that have roles in maintenance or manipulation of the genome
A Critical Role for FBXW8 and MAPK in Cyclin D1 Degradation and Cancer Cell Proliferation
Cyclin D1 regulates G1 progression. Its transcriptional regulation is well understood. However, the mechanism underlying cyclin D1 ubiquitination and its subsequent degradation is not yet clear. We report that cyclin D1 undergoes increased degradation in the cytoplasm during S phase in a variety of cancer cells. This is mediated by phosphorylation at Thr286 through the activity of the Ras/Raf/MEK/ERK cascade and the F-box protein FBXW8, which is an E3 ligase. The majority of FBXW8 is expressed in the cytoplasm during G1 and S phase. In contrast, cyclin D1 accumulates in the nucleus during G1 phase and exits into the cytoplasm in S phase. Increased cyclin D1 degradation is linked to association with FBXW8 in the cytoplasm, and enhanced phosphorylation of cyclin D1 through sustained ERK1/2 signaling. Depletion of FBXW8 caused a significant accumulation of cyclin D1, as well as sequestration of CDK1 in the cytoplasm. This resulted in a severe reduction of cell proliferation. These effects could be rescued by constitutive nuclear expression of cyclin D1-T286A. Thus, FBXW8 plays an essential role in cancer cell proliferation through proteolysis of cyclin D1. It may present new opportunities to develop therapies targeting destruction of cyclin D1 or its regulator E3 ligase selectively
Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers
Age is one of the most important risk factors for human malignancies, including breast cancer; in addition, age-at-diagnosis has been shown to be an independent indicator of breast cancer prognosis. However, except for inherited forms of breast cancer, there is little genetic or epigenetic understanding of the biological basis linking aging with sporadic breast cancer incidence and its clinical behavior
Recommended from our members
Profiling Breast Cancer by Array CGH
Breast tumors display a wide variety of genomic alterations. This review focuses on DNA copy number variations in these tumors as measured by the recently developed microarray-based form of comparative genomic hybridization. The capabilities of this new technology are reviewed. Initial applications of array CGH to the analysis of breast cancer, and the mechanisms by which the particular types of copy number changes might arise are discussed
- …